For the first time in more than a decade, the FDA has approved a new first-line treatment for patients with metastatic #pancreaticcancer, called NALIRIFOX. After a clinical trial showed a positive survival benefit, the combination chemotherapy called NALIRIFOX is now approved for patients who have not received any previous treatment. For a disease with limited treatment options, this is exciting news. 💜 We've answered some of the most common questions related to this new treatment option at pcan.at/s2nut9. If you have additional questions, you can contact PanCAN Patient Services at 📱 877-2- PANCAN or 📧 [email protected]. Our Case Managers can help you understand your options and connect you with resources to learn more.